What I Tell My Patients About...

Treatment Approaches for Nonmetastatic Hormone-Sensitive Prostate Cancer (HSPC)

• Indications to initiate androgen deprivation therapy (ADT)
• Major efficacy and safety findings with the oral LHRH antagonist relugolix in men with advanced PC; optimal integration opposite standard injectable ADT
• Recently presented findings with the addition of abiraterone and prednisolone with or without enzalutamide to ADT for men with high-risk nonmetastatic PC; implications for routine practice
• Ongoing trials evaluating secondary hormonal therapy in nonmetastatic HSPC

Contemporary Management of Nonmetastatic Castration-Resistant PC (CRPC)

• Factors (eg, PSA level and doubling time) in the decision to add secondary hormonal therapy to ADT for PSA-only relapse
• Similarities and differences among apalutamide, enzalutamide and darolutamide
• Research data supporting the use of apalutamide, enzalutamide or darolutamide for biochemical relapse on ADT
• Patient selection for and practical integration of secondary hormonal therapy

Therapeutic Decision-Making for Metastatic HSPC (mHSPC)

• Rationale for treatment intensification with secondary hormonal therapy and/or chemotherapy added to standard ADT for patients presenting with mHSPC
• Long-term data with docetaxel, abiraterone, enzalutamide or apalutamide with ADT; key clinical and practical factors in the selection among these strategies
• Major findings with docetaxel with or without abiraterone with or without local radiation therapy for mHSPC
• Recently reported outcomes with the combination of darolutamide, ADT and docetaxel for patients with mHSPC; potential implications for clinical practice

Tolerability of Hormonal Therapy in the Treatment of PC

• Relative incidence of cardiovascular adverse events (AEs) observed with hormonal agents; appropriate monitoring, management and baseline risk assessment
• Monitoring for and management of CNS-related events in patients receiving antiandrogen therapy
• Effect of hormonal therapy on bone health and skeletal-related events; prevention and management strategies
• Incidence and management of other notable side effects (eg, hot flashes, sarcopenia, rash)

Selection and Sequencing of Therapy for Metastatic CRPC (mCRPC)

• Key factors (eg, prior therapy, symptomatology, site of metastases) influencing treatment recommendations
• Mechanistic similarities and differences between cabazitaxel and docetaxel
• Major efficacy findings from trials investigating the optimal sequencing of cabazitaxel
• Spectrum of common toxicities associated with cabazitaxel; optimal monitoring and management strategies

Radium-223 for mCRPC

• Patient selection and optimal integration in current treatment algorithms
• Incidence, severity and management of common AEs (eg, cytopenias, gastrointestinal toxicity, peripheral edema)
• Fractures associated with radium-223 and secondary hormonal therapy in historical clinical trials; effect of bone-protecting agents in mitigating this risk
• Educating patients about appropriate radiation-protection precautions

Role of ¹⁷⁷Lu-PSMA-617 in mCRPC Management

• Clinical relevance of PSMA expression in PC; mechanism of action of the novel radioligand therapy ¹⁷⁷Lu-PSMA-617
• Key efficacy outcomes with the addition of ¹⁷⁷Lu-PSMA-617 to standard therapy for progressive PSMA-positive mCRPC
• Common treatment-emergent AEs
• Recent FDA approval of ¹⁷⁷Lu-PSMA-617 for mCRPC and optimal placement in the therapeutic sequence

Current Utility of PARP Inhibitors in the Management of Metastatic PC

• Spectrum and frequency of BRCA and other homologous recombination repair (HRR) gene mutations in PC; indications for and practical implementation of genetic testing
• Long-term efficacy and safety findings with olaparib and rucaparib monotherapy for mCRPC
• FDA-approved indications for olaparib or rucaparib and optimal integration into management algorithms

Tolerability and Other Practical Considerations with PARP Inhibitors for PC

• Incidence, timing and severity of common class- and agent-specific toxicities in patients with mCRPC
• Optimal monitoring and management practices
• Initial dosing of approved PARP inhibitors and appropriate dose-modification strategies
• Approaches to encourage adherence among patients receiving long-term oral medications

Future Role of PARP Inhibitors in Therapy for PC

• Biologic basis for combining PARP inhibitors with secondary hormonal therapies
• Available efficacy and safety findings with olaparib and niraparib in combination with abiraterone as first-line therapy for mCRPC with and without HRR gene mutations; implications for clinical management
• Impact on tolerability of combining PARP inhibitors with secondary hormonal therapy
• Other ongoing research evaluating novel applications of PARP inhibitors

Promising Investigational Strategies for PC

• Educating patients about the potential advantages of participating in a clinical research study
• Early findings with and ongoing evaluation of cabozantinib in combination with atezolizumab for mCRPC
• Frequency of PTEN loss in mCRPC; key efficacy and safety data with ipatasertib and abiraterone/prednisone in this population
• Other novel agents and strategies under investigation for PC

Thank you for your interest in our NCPD program taking place in Anaheim, CA. At this time online preregistration for in-person is closed for this event. SEATS ARE STILL AVAILABLE FOR THE SESSION. Our Onsite Registration Desk will be open at 5:30 AM Pacific Time on Thursday, April 28th. If you are interested in attending, please visit our registration desk located outside the Grand Ballroom E-K (Lobby Level) of the Anaheim Marriott hotel (700 West Convention Way) which is within walking distance (0.2 miles) of the Anaheim Convention Center.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.

Please note, onsite registration does not guarantee meal service which will be based on availability.